Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic MigraineBusiness Wire • 07/18/24
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024Business Wire • 07/02/24
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment PausesBusiness Wire • 06/28/24
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020Business Wire • 06/25/24
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United StatesBusiness Wire • 06/24/24
Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/11/24
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/04/24
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)Business Wire • 06/01/24
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024Business Wire • 06/01/24
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)Business Wire • 05/29/24
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsBusiness Wire • 05/15/24
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)Seeking Alpha • 05/14/24